arzoxifene
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Trial Timeline
Jan 1, 2001 → Apr 1, 2007
NCT ID
NCT00190697About arzoxifene
arzoxifene is a approved stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00190697. Target conditions include Breast Cancer, Endometrial Cancer, Ovarian Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00190697 | Approved | Completed |
Competing Products
20 competing products in Breast Cancer